Observational Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Mar 26, 2022; 10(9): 2783-2791
Published online Mar 26, 2022. doi: 10.12998/wjcc.v10.i9.2783
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Representative immunohistochemical staining for Ubiquilin4 expression in cervical cancer specimens. A and B: High expression of Ubiquilin4 (UBQLN4) in cervical cancer, score: 3; C and D: Low expression of UBQLN4 in cervical cancer, score: 2; E and F: Low expression of UBQLN4 in paracervical tissue, score: 1; G and H: Low expression of UBQLN4 in paracervical tissue, score: 0. (A, C, E, and G: Original magnification, 100 ×; B, D, F, and G: Original magnification, 200 ×).
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Expression of the Ubiquilin4 protein in cervical cancer tissue and pericervical tissue cells. The UBQLN4 protein was overexpressed in cervical cancer tissues. IHC: Immunohistochemistry.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Results of the Kaplan–Meier analysis of the association between Ubiquilin4 expression and survival. The overall and the progression-free survival of cervical cancer patients with high and low expression. Log-rank test results showed that the patients with low UBQLN4 staining had a significantly better overall and progression-free survival than the patients with high expression. A: Overall survival; B: Progression-free survival.